Dr. Eric Marks is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine. He currently specializes in gastrointestinal oncology and sarcomas. Dr. Marks graduated from the University of Massachusetts and subsequently pursued medical school and a residency in Internal Medicine at Pennsylvania State University. He then completed his fellowship in hematology and medical oncology at the Warren Alpert Medical School of Brown University, where he published several studies focused on gastrointestinal malignancies.
Diversity, Equity, Inclusion and Accessibility
I am part of a dedicated team of healthcare professionals, researchers, students and staff from different countries and various regions of the U.S. The culture of our Section is defined by the unique perspectives that we each bring with us. As both a large academic medical center and safety-net hospital serving the communities of Boston and its surroundings, our trainees engage in cutting edge research and gain real-world clinical experience by caring for local underserved populations. Our multilingual team is committed to promoting cultural competency, equity and inclusion in science, medicine and healthcare. We strive to maintain a workforce that is as diverse as the communities we serve, and aim to create a safe space for our members to learn, grow and succeed in their life goals. Acknowledging that we all have a role to play, I am dedicated to welcoming and celebrating individuals of all races, ethnicities, social backgrounds, religion, gender, sex, age, ability, sexual orientation, veteran status, and national origin.
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
EMERALD-Y90: Phase II Single-Arm Study of Durvalumab and Bevacizumab
Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy04/18/2024 - 04/17/2027 (PI)
Astrazeneca Pharmaceuticals
DCC-2618-03-003: An International, Phase 3, Randomized, Multicenter, Open label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Pr03/12/2024 - 03/11/2027 (PI)
Deciphera Pharmaceuticals, LLC
Multicenter Phase II Study of Pomalidomide Monotherapy in Kaposi Sarcoma04/01/2023 - 08/31/2025 (PI)
EMMES Corporation
HCRN IPA (02/23/2022) – GI19-40502/23/2022 - 02/29/2024 (PI)
Hoosier Cancer Research Network, Inc.
|
Yr
|
Title
|
Project-Sub Proj
|
Pubs
|
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Marks EI, Matera R, Olszewski AJ, Yakirevich E, El-Deiry WS, Safran H, Carneiro BA. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. Am J Clin Oncol. 2021 02 01; 44(2):68-73. PMID: 33298767
-
Marks EI, Brown VS, Dizon DS. Am J Clin Oncol. Genomic and Molecular Abnormalities in Gynecologic Clear Cell Carcinoma. 2020; 43(2):139-145.
-
Marks EI, Pamarthy S, Dizon D, Birnbaum A, Yakirevich E, Safran H, Carneiro B. ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. Oncotarget. 2019; 10:245-251.
-
Marks EI, Ollila TA. Acanthocytosis causing chronic hemolysis in a patient with advanced cirrhosis. Blood. 2019; 133:1518.
-
Lipton A, Leitzel K, Ali SM, Polimera HV, Nagabhairu V, Marks E, Richardson AE, Krecko L, Ali A, Koestler W, Esteva FJ, Leeming DJ, Karsdal MA, Willumsen N. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer. 2018 12 01; 143(11):3027-3034. PMID: 29923614; DOI: 10.1002/ijc.31627;
-
Yacur M, Marks EI, Suleski J, Joshi M. Expression of Beta-Human Chorionic Gonadotropin (BetaHCG) in Transitional Cell Carcinoma. Annals of Carcinogenesis. 2017; 2(2):1012-1016.
-
Marks EI, Yee NS. Molecular genetics and targeted therapeutics in biliary tract carcinoma. World J Gastroenterol. 2016 Jan 28; 22(4):1335-47. PMID: 26819503; PMCID: PMC4721969; DOI: 10.3748/wjg.v22.i4.1335;
-
Marks EI, Yee NS. World J of Gastroenterol. Molecular genetics and targeted therapeutics in biliary tract carcinoma. 2016; 22(4):1335-1347.
-
Marks EI, Yee NS. Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. World J Gastrointest Oncol. 2015 Nov 15; 7(11):338-46. PMID: 26600933; PMCID: PMC4644856; DOI: 10.4251/wjgo.v7.i11.338;
-
Marks EI, Yee NS. World J Gastrointest Oncol. Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. 2015; 7(333):338-346.
Showing 10 of 15 results.
Show More
-
Marks EI, Yee NS. Curr Cancer Drug Targets. Molecular Genetics and Targeted Therapy in Hepatocellular Carcinoma. 2015; 16:53-70.
-
Marks E, Rizvi SM, Sarwani N, Yang Z, El-Deiry WS. A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases. Cancer Biol Ther. 2015; 16:377-382.
-
Marks EI, Brennan M, El-Deiry WS. Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Cancer Biol Ther. 2015; 16:1136-1139.
-
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015; 16(12):1710-1719.
-
Marks EI, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, El-Deiry WS. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. 2015; 16(12):1710-9. PMID: 26561209; PMCID: PMC4847811; DOI: 10.1080/15384047.2015.1113355;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
2019 Brown University:
Certificate of exemplary teaching
2016 Penn State Cancer Institute house-staff award for clinical performance